...Ltd. as CMO and CFO, respectively. Johns was CMO and EVP of medical and scientific affairs at Syntimmune Inc. Dorton...
...pyrin domain containing 3 Danielle Golovin Sarepta Therapeutics Inc. Iovance Biotherapeutics Inc. Gritstone Oncology Inc. SpringWorks Therapeutics Inc. NodThera Ltd. Repare Therapeutics Inc. Syntimmune Inc. NLR...

...to deals for clinical-stage companies. Its takeouts of Achillion Pharmaceuticals Inc. last year, and of Syntimmune Inc....

...strategy to maintain that position includes adding an FCRN inhibitor through its 2018 takeout of Syntimmune Inc....

...bought two companies last year, paying $400 million up front for rare autoimmune disease company Syntimmune Inc....

...company Cadent Therapeutics inc. (Cambridge, Mass.) hired John McBride as CFO. He was CFO of Syntimmune Inc....

...antibody company in 1992. Kress served as president and CEO of rare autoimmune disease company Syntimmune Inc....

...Led by former Syntimmune CEO David de Graaf, Comet launched Wednesday with $28.5 million in series...
...as fatty acid synthesis, regulation of gene expression and energy production. de Graaf’s previous company, Syntimmune Inc....
...for $400 million up front and a potential $800 million in milestones last year (see “Syntimmune...

...a director of the red blood cell-based therapeutic company. Kress was CEO and chairman of Syntimmune Inc....

...disclose indications this year. Last year, Alexion gained FCRN-targeting mAb SYNT001 via its takeout of Syntimmune Inc....
...hemolytic anemia and a Phase Ib/II trial to treat pemphigus vulgaris or pemphigus foliaceus (see "Syntimmune...

...Mass.) hired Mario Saltarelli as CMO, a new position. He was EVP and CMO of Syntimmune Inc....